

Final Draft Agenda
31st meeting of the Committee for Socio-economic Analysis

31 May - 9 June 2016

ECHA Conference Centre (Annankatu 18, Helsinki)

31 May starts at 10.00
3 June breaks at 13.00
7 June resumes at 14.00
9 June ends at 14.00

Item 1 – Welcome and Apologies

Item 2 – Adoption of the Agenda

SEAC/A/31/2016
For adoption

Item 3 – Declarations of conflicts of interest to the Agenda

Item 4 – Report from other ECHA bodies and activities

- a) Report on SEAC-30 action points, written procedures and update on other ECHA bodies

SEAC/31/2016/01
For information

Item 5 – Restrictions

5.1 General restriction issues

- a) Update on Forum restrictions projects

For information

5.2 Restriction Annex XV dossiers

a) Opinion development

- 1) D4/D5 – draft final opinion

For adoption

b) Conformity check

- 1) TDFAs – outcome of the conformity check and presentation of the key issues
- 2) Diisobutyl phthalate (DIBP), Dibutyl phthalate (DBP), Benzyl butyl phthalate (BBP), Bis(2-ethylhexyl) phthalate (DEHP) – outcome of the conformity check and presentation of the key issues

For agreement

5.3 Appointment of (co-)rapporteurs for restriction dossiers

For information

Item 6 – Authorisation

6.1 General authorisation issues

a) Update on incoming/future applications

For information

b) AfA: Capacity building:

- The social cost of unemployment

SEAC/31/2016/02

For discussion

- Willingness-to-pay values for various health endpoints associated with chemicals exposure

SEAC/31/2016/03

For discussion and agreement

c) Report of the AfA task force activities

For information

6.2 Authorisation applications

a) Outcome of the conformity check and presentation of the key issues

1. Chromium trioxide_SNECMA
2. Chromium trioxide_MTU

3. Chromium trioxide_ABLOY
4. Chromium trioxide_HOOGOSENS Court Roll Surface Technologies
5. Chromium trioxide_TOPOCROM GmbH
6. Chromium trioxide_FN HERSTAL S.A.
7. Chromium trioxide_GERARDHI KUNSTOFFTECHNIK GmbH
8. Chromium trioxide; Potassium dichromate; Sodium dichromate_SOURIAU SAS
9. Chromium trioxide_HAPPOC
10. Ammonium dichromate_VECO BV
11. Potassium dichromate_GENTROCHEMA BV
12. Sodium dichromate_GENTROCHEMA BV
13. Sodium dichromate_TOTAL RAFFINERIE MITTELDEUTSCHLAND GmbH
14. Sodium dichromate_JACOBS DOUWEE EGBERTS DE GmbH
15. EDC_BASF SE
16. EDC_ELI LILLY S.A.
17. EDC_DOW ITALIA S.R.L.
18. EDC_LANXESS Deutschland GmbH
19. EDC_H&R OLWERKE SCHINDLER GmbH
20. EDC_GRUPPA LOTOS S.A.
21. EDC_GE HEALTHCARE Bio-Sciences
22. Diglyme_ROCHE DIAGNOSTIC GmbH
23. Diglyme_LIFE TECHNOLOGIES A.S.
24. Diglyme_BRACCO IMAGING S.P.A.
25. Diglyme_MAFOLON S.P.A.
26. Diglyme_ACTON TECHNOLOGIES Limited
27. Diglyme_ISOCEM
28. Technical MDA_POLYNT COMPOSITES France
29. EDC_EURENCO

For discussion and agreement

b) Agreement on draft opinions

1. Chromium trioxide 1 (5 uses) (CT_Lanxess) – third version of the draft opinion
2. Sodium dichromate-Akzo Nobel (2 uses) (SD_Akzo)
3. Sodium dichromate-Solvay (1 use) (SD_Solvay)
4. Sodium dichromate-Arkema (1 use) (SD_Arkema)
5. Sodium dichromate-Ercros (1 use) (SD_Ercros)
6. Sodium dichromate-Electroquimica (1 use) (SD_ELECTRQUIMICA)
7. Sodium dichromate-Kemira (1 use) (SD_Kemira)
8. Sodium dichromate-Caffaro Brescia (1 use) (SD_Caffaro)
9. Chromium trioxide-Federal-Mogul Friedberg (1 use) (CT_Friedberg)
10. Chromium trioxide-Federal-Mogul Valvetrain (1 use) (CT_Valvetrain)
11. Chromium trioxide-Federal-Mogul Burscheid (1 use) (CT_Burscheid)
12. Chromic acid-Bosch (1 use) (CA_Bosch)

13. Chromium trioxide-Circuit Foil Luxembourg (1 use) (CT_Circuit)
14. Arsenic acid-Circuit Foil Luxembourg (1 use) (AsA_Circuit)
15. Chromium trioxide and dichromium tris(chromate)-Nexter Mechanics (4 uses) (CT_DtC_Nexter)
16. Chromium trioxide-Praxair (2 uses) (CT_Praxair)
17. Potassium dichromate-Sofradir (2 uses) (PD_Sofradir)
18. Sodium dichromate-Lanxess (1 use) (SD_Lanxess)
19. Ammonium dichromate-Micrometal (1 use) (AD_Micrometal)
20. Chromium trioxide-Cromomed (1 use) (CT_Cromomed)
21. Chromium trioxide-Rimex Metals (1 use) (CT_Rimex)
22. EDC-BASF (1 use) (EDC_BASF)
23. Diglyme-Novartis (1 use) (Diglyme_Novartis)

For discussion and agreement

c) Orientation discussion

1. Sodium dichromate-Brenntag (3 uses) (SD_Brenntag)
2. Potassium dichromate-Brenntag (2 uses) (PD_Brenntag)
3. Dichromium tris(chromate)-Henkel (2 uses) (DtC_Henkel)
4. Strontium chromate-Akzo Nobel (2 uses) (SC_Akzo)
5. Potassium hydroxyoctaoxidizincatedichromate-PPG (2 uses) (PH_PPG)

For discussion

6.3 Appointment of (co-)rapporteurs for authorisation applications (closed session)

***SEAC/31/2016/04
(restricted room document)
For agreement***

Item 7 – AOB

a) Update of the work plan

For information

b) Report from the PBT working group

***SEAC/31/2016/05
For agreement***

c) Outcome of 2015 stakeholder survey

For information

d) Benefits of REACH and ECHA's second 5-year report on REACH and CLP

For information

- e) Report on health costs that may be associated with endocrine disrupting chemicals

For information

Item 8 – Action points and main conclusions of SEAC-31

Table with Conclusions and Action points from SEAC-31

For adoption